Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare progression-free survival (PFS) of patients
with metastatic triple-negative breast cancer randomised to treatment with standard
chemotherapy plus moxifloxacin or placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Anti-Bacterial Agents Carboplatin Gemcitabine Moxifloxacin Norgestimate, ethinyl estradiol drug combination